Industry Verticals »

All Categories

Insights »

About TMR »

T-cell Acute Lymphoblastic Leukemia Market

Schedule a Call

T-cell Acute Lymphoblastic Leukemia Market

T-cell Acute Lymphoblastic Leukemia Market (Treatment - Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, Immunotherapy; End user - Hospital, Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global T-cell Acute Lymphoblastic Leukemia Market - Snapshot

The global T-cell acute lymphoblastic leukemia market is driven by rise in prevalence of T-cell acute lymphoblastic leukemia. The global market is projected to grow at a rapid pace during the forecast period. This is attributed to increase in cancer awareness programs and strong product pipeline.

T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia, with features similar to lymphoma. It affects white blood cells called T lymphocytes. T-ALL is most common among children aged over 5 years. Treatment of this disease includes chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. Rise in prevalence of T-ALL and rapid technological advancements boost the global T-cell acute lymphoblastic leukemia market. According to the American Society of Clinical Oncology (ASCO), T-cell acute lymphoblastic leukemia accounted for 15% to 20% of all acute lymphoblastic leukemia. According to a recent study, in 2017, nearly 5,970 cases of acute lymphoblastic leukemia (ALL) were reported in the U.S. About 4 in 10 cases were in adults. Moreover, increase in health care expenditure and rise in number of clinical trials are expected to fuel the global T-cell acute lymphoblastic leukemia market.

t-cell-acute-lymphoblastic-leukemia-market.jpg

The global T-cell acute lymphoblastic leukemia market has been segmented based on treatment, end-user, and region. In terms of treatment, the global market has been classified into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The chemotherapy treatment segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at a significant CAGR during the forecast period due to its high prescription rate, wide range of products, and easy availability.

Based on end-user, the global T-cell acute lymphoblastic leukemia market has been categorized into hospitals, clinics, and others. The hospitals segment dominated the global market in 2017, and the trend is likely to continue during the forecast period. This is attributed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness among individuals about T-ALL. Moreover, hospitals provide advanced medical treatment to treat T-cell acute lymphoblastic leukemia patients.

In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to gain market share by the end of 2026. The market in North America is driven by increase in incidence of T-cell acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. The T-cell acute lymphoblastic leukemia market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Japan dominated the T-cell acute lymphoblastic leukemia market in the region. The market in India is expected to expand at a high CAGR during the forecast period.

Major players operating in the global T-cell acute lymphoblastic leukemia market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma, Inc., and Celgene Corporation. These companies have adopted the strategy of acquisition and collaboration in order to strengthen their positions in the global market.

Increasing Cases of Cancer and Leukemia to Attract Higher Revenues for T-cell Acute Lymphoblastic Leukemia Market

The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia is likely to emerge as the key driver of the global T-cell acute lymphoblastic leukemia market. White blood cell acute lymphoblastic leukemia (T-ALL) is a kind of acute lymphoblastic leukemia, with highlights like lymphoma. It influences white platelets called T lymphocytes. T-ALL is generally basic among kids matured more than 5 years. Therapy of this illness incorporates chemotherapy, radiation treatment, bone marrow relocate, directed treatment, and immunotherapy. Ascend in pervasiveness of T-ALL and fast innovative progressions help the worldwide T-cell acute lymphoblastic leukemia market. Also, expansion in medical services use and ascend in number of clinical preliminaries are required to fuel the worldwide T-cell acute lymphoblastic leukemia market.

Advancement in the drug area, government drives, rising medical care consumption, flood in innovative work, and flooding number of in persistent pool are assessed to spread out the worldwide market. Request regarding therapeutics for T-cell acute lymphoblastic leukemia has developed significantly in the recent years. This brought about expansion in clinical preliminaries in ahead of schedule and late phases of prescription turn of events.

Regionwise, North America held the largest share in the past and is likely to continue so in the coming years. This is attributed to the rising rate of T-cell acute lymphoblastic leukemia, new item endorsements, solid item pipeline, and ascend in medical care consumption. The T-cell acute lymphoblastic leukemia market in Asia Pacific is expected to develop at a quick speed during the estimate time frame. Japan ruled the T-cell acute lymphoblastic leukemia market around there.

Flooding progression in innovation and R&D exercises identified with assembling methods are projected to drill the profitability of drug advancement. In any case, staggering cost related with the treatment of T-cell acute lymphoblastic leukemia is expected to control the market in the approaching years. Advancement of therapeutics requires the usage of expensive instrumentation that also grows the overall expense of therapeutics and treatment for the illness.

The global T-cell acute lymphoblastic leukemia market has been segmented as below:

by Treatment
  • Chemotherapy
  • Radiation Therapy
  • Bone Marrow Transplant
  • Targeted Therapy
  • Immunotherapy

by End-user
  • Hospitals
  • Clinics
  • Others

by Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market

    4. Market Overview
         4.1. Introduction
         4.2. Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
         4.3. Global T-cell Acute Lymphoblastic Leukemia Market Outlook
         4.4. Key Industry Developments
         4.5. T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
         4.6. Nelarabine: Clinical Trial
         4.7. Acute Lymphocytic Leukemia New Cases, 2017
         4.8. Reimbursement Scenario for Cancer Treatment
         4.9. Regulatory Guidelines for Therapeutics

    5. Market Dynamics
         5.1. Drivers and Restraints Snapshot Analysis
         5.2. Drivers
         5.3. Restraints
         5.4. Opportunities
         5.5. Key Trends

    6. Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
         6.1. Introduction
         6.2. Global T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         6.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                6.3.1. Chemotherapy
                6.3.2. Radiation Therapy
                6.3.3. Bone Marrow Transplant
                6.3.4. Targeted Therapy
                6.3.4. Immunotherapy

    7. Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
         7.1. Key Findings
         7.2. Introduction
         7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         7.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by End-user
         7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End-user
                7.5.1. Hospitals
                7.5.2. Clinics
                7.5.3. Others
         7.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    8. T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region
         8.1. Key Findings
         8.2. Global Market Scenario
         8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
         8.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by Region
                8.4.1. North America
                8.4.2. Europe
                8.4.3. Asia Pacific
                8.4.4. Latin America
                8.4.5. Middle East & Africa
         8.5. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region

    9. North America T-cell Acute Lymphoblastic Leukemia Market
         9.1. Key Findings
         9.2. North America T-cell Acute Lymphoblastic Leukemia Market Overview
         9.3. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
         9.4. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country
                9.4.1. U.S.
                9.4.2. Canada
         9.5. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         9.6. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                9.6.1. Chemotherapy
                9.6.2. Radiation Therapy
                9.6.3. Bone Marrow Transplant
                9.6.4. Targeted Therapy
                9.6.4. Immunotherapy
         9.7. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         9.8. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
                9.8.1. Hospitals
                9.8.2. Clinics
                9.8.3. Others
         9.9. North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    10. Europe T-cell Acute Lymphoblastic Leukemia Market
         10.1. Key Findings
         10.2. Europe T-cell Acute Lymphoblastic Leukemia Market Overview
         10.3. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
         10.4. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Spain
                10.4.5. Italy
                10.4.6. Rest of Europe
         10.5. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         10.6. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                10.6.1. Chemotherapy
                10.6.2. Radiation Therapy
                10.6.3. Bone Marrow Transplant
                10.6.4. Targeted Therapy
                10.6.4. Immunotherapy
         10.7. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         10.8. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
                10.8.1. Hospitals
                10.8.2. Clinics
                10.8.3. Others
         10.9. Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    11. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market
         11.1. Key Findings
         11.2. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Overview
         11.3. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
         11.4. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
                11.4.1. China
                11.4.2. Japan
                11.4.3. India
                11.4.4. Australia & New Zealand
                11.4.5. Rest of APAC
         11.5. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         11.6. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                11.6.1. Chemotherapy
                11.6.2. Radiation Therapy
                11.6.3. Bone Marrow Transplant
                11.6.4. Targeted Therapy
                11.6.4. Immunotherapy
         11.7. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         11.8. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
                11.8.1. Hospitals
                11.8.2. Clinics
                11.8.3. Others
         11.9. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    12. Latin America T-cell Acute Lymphoblastic Leukemia Market
         12.1. Key Findings
         12.2. Latin America T-cell Acute Lymphoblastic Leukemia Market Overview
         12.3. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
         12.4. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of LATAM
         12.5. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         12.6. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                12.6.1. Chemotherapy
                12.6.2. Radiation Therapy
                12.6.3. Bone Marrow Transplant
                12.6.4. Targeted Therapy
                12.6.4. Immunotherapy
         12.7. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         12.8. Latin America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
                12.8.1. Hospitals
                12.8.2. Clinics
                12.8.3. Others
         12.9. Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market
         13.1. Key Findings
         13.2. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Overview
         13.3. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
         13.4. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
                13.4.1. GCC Countries
                13.4.2. Israel
                13.4.3. South Africa
                13.4.4. Rest of MEA
         13.5. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
         13.6. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
                13.6.1. Chemotherapy
                13.6.2. Radiation Therapy
                13.6.3. Bone Marrow Transplant
                13.6.4. Targeted Therapy
                13.6.4. Immunotherapy
         13.7. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
         13.8. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
                13.8.1. Hospitals
                13.8.2. Clinics
                13.8.3. Others
         13.9. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

    14. Competition Landscape
         14.1. Market Player - Competition Matrix (By Tier and Size of companies)
         14.2. Market Share Analysis, by Company (2017)
         14.3. Company Profiles
                14.3.1. Pfizer, Inc.
                         14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.1.2. Financial Overview
                         14.3.1.3. Product Portfolio
                         14.3.1.4. SWOT Analysis
                         14.3.1.5. Strategic Overview
                14.3.2. Novartis AG
                         14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.2.2. Financial Overview
                         14.3.2.3. Product Portfolio
                         14.3.2.4. SWOT Analysis
                         14.3.2.5. Strategic Overview
                14.3.3. F. Hoffmann-La Roche Ltd.
                         14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.3.2. Financial Overview
                         14.3.3.3. Product Portfolio
                         14.3.3.4. SWOT Analysis
                         14.3.3.5. Strategic Overview
                14.3.4. Sanofi
                         14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.4.2. Financial Overview
                         14.3.4.3. Product Portfolio
                         14.3.4.4. SWOT Analysis
                         14.3.4.5. Strategic Overview
                14.3.5. Erytech Pharma Inc.
                         14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.5.2. Financial Overview
                         14.3.5.3. Product Portfolio
                         14.3.5.4. SWOT Analysis
                         14.3.5.5. Strategic Overview
                14.3.6. Celgene Corporation
                         14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.3.6.2. Financial Overview
                         14.3.6.3. Product Portfolio
                         14.3.6.4. SWOT Analysis
                         14.3.6.5. Strategic Overview

    List of Tables

    Table 01: T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
    Table 02: Nelarabine: Clinical Trial
    Table 03: Authorities Responsible for Reimbursement of Medicines in European Region, 2017
    Table 04: Major Regulatory Agencies Responsible for Granting Marketing Authorization for Drugs
    Table 05: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 06: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
    Table 07: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 08: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 09: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 10: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
    Table 11: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 12: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 13: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
    Table 14: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 15: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 16: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
    Table 17: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 18: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 19: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
    Table 20: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 21: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
    Table 22: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
    Table 23: Products Offered (Pfizer, Inc.)
    Table 24: Products Offered (Novartis AG)
    Table 25: Products Offered (F. Hoffmann-La Roche Ltd.)
    Table 26: Products Offered (Sanofi)
    Table 27: Products Offered (Erytech Pharma, Inc.)
    Table 28: Products Offered (Celgene Corporation)

    List of Figures

    Figure 01: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
    Figure 02: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2017
    Figure 03: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by End-user, 2017
    Figure 04: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Region, 2017 
    Figure 05: Regulatory Approval Process - U.S.
    Figure 06: Regulatory Approval Process - Europe 
    Figure 07: Regulatory Approval Process - Japan
    Figure 08: Global T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 09: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 10: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy, 2016–2026
    Figure 11: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
    Figure 12: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant, 2016–2026
    Figure 13: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
    Figure 14: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
    Figure 15: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 16: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals
    Figure 17: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
    Figure 18: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
    Figure 19: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
    Figure 20: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
    Figure 21: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018–2026
    Figure 22: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 23: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
    Figure 24: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
    Figure 25: North America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 26: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 27: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 28: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
    Figure 29: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 30: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 31: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 32: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 33: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 34: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 35: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
    Figure 36: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 37: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 38: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 39: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 40: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 41: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 42: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
    Figure 43: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 44: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 45: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 46: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 47: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 48: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 49: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
    Figure 50: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
    Figure 51: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 52: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 53: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
    Figure 54: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
    Figure 55: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
    Figure 56: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
    Figure 57: Global T-cell Acute Lymphoblastic Leukemia Market Share, by Company, 2017
    Figure 58: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 59: Pfizer, Inc. Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 60: Pfizer, Inc. Revenue Share (%), by Business Segment, 2017
    Figure 61: Pfizer, Inc. Revenue Share (%), by Region, 2017
    Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 63: Novartis AG Oncology Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 64: Novartis AG Net Sales (%), by Business Segment, 2017
    Figure 65: Novartis AG Net Sales (%), by Region, 2017
    Figure 66: F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
    Figure 67: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
    Figure 68: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Specialty (2017)
    Figure 69: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue (%), by Region (2017)
    Figure 70: Sanofi Revenue (US$ Bn), 2014-2017
    Figure 71: Sanofi Regional Sales Breakdown (%), 2017
    Figure 72: Celgene Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 73: Celgene Corporation Marketing & Sales and R&D Expenses (%), 2015–2017
    Figure 74: Celgene Corporation Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 75: Celgene Corporation Breakdown of Net Sales (%), by Region, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved